Abbott's (ABT) Assert-IQ Cardiac Monitor Receives CE Mark

Zacks03-28

Abbott Laboratories, Inc. ABT recently announced the receipt of CE Mark in Europe for its Assert-IQ insertable cardiac monitor (ICM). The ICM offers physicians a new option for diagnostic evaluation ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2422421519?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZcqDt7bCeBMLkGs_KJ1O8A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/228e67967b066e7a755ae3614be720e1","is_english":true,"pubTime":"2024-03-28 00:25","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2422421519","market":"us","top_or_hot":-1,"title":"Abbott's (ABT) Assert-IQ Cardiac Monitor Receives CE Mark","media":"Zacks","content":"<div>\n<p>Abbott Laboratories, Inc. ABT recently announced the receipt of CE Mark in Europe for its Assert-IQ insertable cardiac monitor (ICM). The ICM offers physicians a new option for diagnostic evaluation ...</p>\n\n<a href=\"https://finance.yahoo.com/news/abbotts-abt-assert-iq-cardiac-162500412.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Abbott's (ABT) Assert-IQ Cardiac Monitor Receives CE Mark</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbott's (ABT) Assert-IQ Cardiac Monitor Receives CE Mark\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-28 00:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/abbotts-abt-assert-iq-cardiac-162500412.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Abbott Laboratories, Inc. ABT recently announced the receipt of CE Mark in Europe for its Assert-IQ insertable cardiac monitor (ICM). The ICM offers physicians a new option for diagnostic evaluation ...</p>\n\n<a href=\"https://finance.yahoo.com/news/abbotts-abt-assert-iq-cardiac-162500412.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4084","symbol_name":"特种房地产投资信托","start_time":0,"source_url":"https://finance.yahoo.com/news/abbotts-abt-assert-iq-cardiac-162500412.html","article_id":"2422421519","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZcqDt7bCeBMLkGs_KJ1O8A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/228e67967b066e7a755ae3614be720e1"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2422421519","pubTimestamp":1711556700,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Abbott Laboratories, Inc. ABT recently announced the receipt of CE Mark in Europe for its Assert-IQ insertable cardiac monitor . The ICM offers physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing abnormal heartbeats.Abbott, which pioneered the launch of the world's first Bluetooth-enabled ICM, is now again fuelling innovation in arrhythmia control with the Assert-IQ ICM. The newest technology allows regular monitoring of abnormal heart rhythms, as well as technologies to improve data management and workflow.The recent development will bolster Abbott's cardiac rhythm management business.Abbott has added Assert-IQ ICM to its expanding line of linked health devices. It can identify even hard-to-spot anomalies in heartbeats and assist doctors in choosing the most appropriate course of action.Abbott's Assert-IQ ICM uses bluetooth technology to pair with a transmitter, typically the user's mobile phone, to monitor cardiac rhythms every 20 seconds","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4084":"特种房地产投资信托","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","BK4552":"Archegos爆仓风波概念","BK4505":"高瓴资本持仓","BK4581":"高盛持仓","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU0122379950.USD":"贝莱德世界健康科学A2","LU2404859667.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","CAH":"卡地纳健康","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SYK":"史赛克","LU0690374615.EUR":"FUNDSMITH EQUITY \"R\" (EUR) ACC","IQ":"爱奇艺","BK4529":"IDC概念","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","ABT":"雅培","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","COR":"CENCORA","BK4592":"伊斯兰概念","BK4109":"特种化学制品","BK4531":"中概回港概念","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4108":"电影和娱乐","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","CE":"塞拉尼斯","BK4526":"热门中概股","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4588":"碎股","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","GB00B4LPDJ14.GBP":"FUNDSMITH EQUITY \"R\" (GBP) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","BK4082":"医疗保健设备","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","SG9999002232.USD":"Allianz Global High Payout USD","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC"},"translate_title":"雅培（ABT）Assert-IQ心脏监护仪获得CE认证","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SYK":1,"ABT":1,"IQ":1,"COR":1,"CE":1,"CAH":0.9},"content_text":"Abbott Laboratories, Inc. ABT recently announced the receipt of CE Mark in Europe for its Assert-IQ insertable cardiac monitor (ICM). The ICM offers physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing abnormal heartbeats.\nAbbott, which pioneered the launch of the world's first Bluetooth-enabled ICM, is now again fuelling innovation in arrhythmia control with the Assert-IQ ICM. The newest technology allows regular monitoring of abnormal heart rhythms, as well as technologies to improve data management and workflow.\nThe recent development will bolster Abbott's cardiac rhythm management business.\nMore on Assert-IQ ICM\nAbbott has added Assert-IQ ICM to its expanding line of linked health devices. It can identify even hard-to-spot anomalies in heartbeats and assist doctors in choosing the most appropriate course of action.\nAbbott's Assert-IQ ICM uses bluetooth technology to pair with a transmitter, typically the user's mobile phone, to monitor cardiac rhythms every 20 seconds and send critical results to the clinic's portal almost instantly. Assert-IQ provides the longest battery life available for a bluetooth-enabled ICM.\n\nImage Source: Zacks Investment Research\nOther ICMs on the market track an individual's heartbeat for a few years, but Assert-IQ offers two options — one with a battery life of at least three years and the other with a battery life of at least six years. Both choices offer sophisticated algorithms that can identify abnormal heartbeats and deliver data that can be used in therapeutic settings. Assert-IQ ICM's enhanced algorithms lessen data load and boost device accuracy, which eventually enhances physician productivity.\nSignificance of Assert-IQ ICM\nAs the prevalence of irregular heart rhythms rises, physicians are increasingly turning to ICM technology to diagnose a variety of cardiac diseases. Introducing Assert-IQ across Europe will provide access to the revolutionary benefits of long-term monitoring and more clinically relevant information, enabling care professionals to make clinical decisions faster and more precisely.\nThe Assert-IQ implantable cardiac monitor is the next generation in medical technology, offering doctors new patient insights and actionable data. Doctors may now provide more individualized and efficient care because of real-time data, advanced algorithms and accurate diagnosis.\nIndustry Prospects\nPer a report by Mordor Intelligence, the Cardiac Arrhythmia monitoring devices market size is estimated at $8.23 billion in 2024 and is expected to reach $11.91 billion by 2029, growing at a CAGR of 7.67%. The market's growth can be primarily attributed to the increasing use of telecardiology, ease of use and portability of cardiac arrhythmia monitoring devices and the development of smart cardiac monitors.\nRecent Developments\nIn January 2024, Abbott announced that the first global procedures had been conducted using the company's new Volt Pulsed Field Ablation (PFA) System to treat patients battling common abnormal heart rhythms such as atrial fibrillation (AFib). Abbott's Volt PFA System is designed to overcome the limitations of first-generation PFA systems by providing physicians a clearer indication of contact between the Volt PFA Catheter and targeted tissue\nEarlier in September 2023, Abbott took a significant step in the field of electrophysiology with the introduction of its TactiFlex Ablation Catheter, Sensor Enabled. This device is designed to treat atrial fibrillation (AFib), a common and potentially life-threatening irregular heart rhythm that affects millions worldwide.\nPrice Performance\nIn the past six months, ABT’s shares have gained 14.8% compared with the industry’s rise of 11.6%.\nZacks Rank and Key Picks\nAbbott currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks from the broader medical space are Stryker Corporation SYK, Cencora, Inc. COR and Cardinal Health CAH.\nStryker, carrying a Zacks Rank #2 (Buy), reported a fourth-quarter 2023 adjusted EPS of $3.46, beating the Zacks Consensus Estimate by 5.8%. Revenues of $5.8 billion outpaced the consensus estimate by 3.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nStryker has an estimated earnings growth rate of 11.5% for 2025 compared with the S&P 500’s 9.9%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 5.1%.\nCencora, carrying a Zacks Rank #2, reported a first-quarter fiscal 2024 adjusted EPS of $3.28, which beat the Zacks Consensus Estimate by 14.7%. Revenues of $72.3 billion outpaced the Zacks Consensus Estimate by 5.1%.\nCOR has an earnings yield of 5.75% compared with the industry’s 1.85%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 6.7%.\nCardinal Health, carrying a Zacks Rank #2, reported second-quarter fiscal 2024 adjusted earnings of $1.82, which beat the Zacks Consensus Estimate by 16.7%. Revenues of $57.45 billion improved 11.6% on a year-over-year basis and also topped the Zacks Consensus Estimate by 1.1%.\nCAH has a long-term estimated earnings growth rate of 15.3% compared with the industry’s 11.8% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.6%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAbbott Laboratories (ABT) : Free Stock Analysis Report\nStryker Corporation (SYK) : Free Stock Analysis Report\nCardinal Health, Inc. (CAH) : Free Stock Analysis Report\nCencora, Inc. (COR) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2422421519"}